Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Child’s Death Leads Beijing Health Officials To Suspend Use Of Sinovac’s Hepatitis A Vaccine

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - District Health Services Bureau officials in Beijing have suspended the use of one batch of Sinovac's inactivated hepatitis A vaccine, Healive, while investigating a possible adverse drug reaction and death of a two-year-old girl who was administered the vaccine

You may also be interested in...



Sinovac To Start Clinical Trials For Hep A Vaccine In Ukraine; First Overseas Steps

SHANGHAI - Sinovac has inked a deal with Ukraine-based Biolik Biopharmaceutical to conduct clinical trials for its inactivated hepatitis A vaccine Healive in Ukraine, the company announced on Sept. 15

Sinovac To Launch New Vaccines In China; Chinese Government Biggest Purchaser

SHANGHAI - Sinovac saw increased income and profits from vaccine sales, including a first order for hepatitis vaccines placed by the Chinese government during the Sichuan earthquake in the first half of the year, according to financial results for the period ended June 30

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC067572

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel